|
Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - LabCorp |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - LabCorp |
|
|
|
Stock and Other Ownership Interests - LabCorp |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - Dava Oncology (I) |
Consulting or Advisory Role - AstraZeneca; Genentech; Novartis; Pfizer |
Travel, Accommodations, Expenses - DAVA Pharmaceuticals; Genentech; Novartis; Pfizer |
Other Relationship - AstraZeneca; Genentech; Novartis; Pfizer |